Sipuleucel-T in management of favorable-risk prostate cancer: the ProVent trial

At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …

Immunotherapy for men on active surveillance?

So one of the more interesting things to be announced since your sitemaster arrived at the annual meeting of the American Urological Association (AUA) in San Francisco yesterday was this one: … READ MORE …

Can Provenge come back from the moribund?

It wouldn’t be wise to expect anything big in a hurry, but it is now clear that the Sanpower Group, which acquired Dendreon about a year ago, has serious plans to do things that the “old Dendreon” never did to optimize the potential of sipuleucel-T (Provenge). … READ MORE …

Can a “new Dendreon” re-make Provenge?

At the end of last week, Dendreon finally became a self-standing, wholly owned subsidiary of the Chinese company known as the Sanpower Group. … READ MORE …

Why do African Americans do better on Provenge than whites?

In general, being of African American race is not a good thing when it comes to prostate cancer-related risk (for getting diagnosed with the disease or for outcomes over time). However, … … READ MORE …

Another new owner for Provenge

According to a media release issued rather quietly a week ago, a large Chinese conglomerate has now bought Provenge (sipuleucel-T) from Valeant, which had acquired it when Valeant bought Dendreon. … READ MORE …

Immunotherapy for the treatment of prostate cancer

The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is available on line. … READ MORE …